Key Takeaways
- Gene and cell therapies offer potential cures for rare diseases by targeting underlying genetic mutations.
- Successful therapy development requires prioritizing patient values, clear risk communication, and long-term support.
- High costs and geographic disparities remain the primary barriers to equitable global access.
- Collaboration between pharma, policymakers, and advocacy groups is essential to align innovation with patient needs.
Patient perspectives on cell and gene therapies
Gene and cell therapies are transforming rare disease treatment by targeting underlying genetic causes rather than managing symptoms alone. Gene therapy modifies a person's genes to treat or cure disease. It can work through several mechanisms: replacing a disease-causing gene with a healthy copy, inactivating a gene that is not functioning properly, or introducing a new or modified gene to help treat a disease. Cell therapy replaces or repairs damaged cells, often using genetically modified cells derived from the patient. These approaches are particularly relevant for diseases caused by single gene mutations, where correcting the root cause can produce durable outcomes.
The way these therapies are delivered varies significantly. Some use modified viruses, known as viral vectors, to carry therapeutic genes into human cells. Others rely on gene editing technology to disrupt or repair specific mutations directly. In ex vivo approaches, cells are removed from the patient, genetically modified in a laboratory, and then returned. Each method carries distinct risk profiles, procedural requirements, and implications for patient experience. For patients and their families, understanding these differences is an important part of informed decision-making, and a frequent source of confusion when information is not communicated clearly.
For these therapies to succeed, development programs must account for patient experience at every stage. Patients need clear, accessible information about treatment benefits, risks, and long-term effects. Without it, engagement and retention suffer.
Access remains a significant barrier. High treatment costs restrict availability, particularly in lower-income regions where conditions like sickle cell disease are most prevalent. Reducing the operational burden on patients, for example through at-home testing and remote engagement models, can help extend the reach of these programs and improve the likelihood that eligible patients participate."
Stakeholder recommendations
The whitepaper expands on the following recommendations for relevant stakeholders.
For pharma and biotech:
- Communicate risks and benefits clearly.
- Implement multi-stage consent processes.
- Provide condition-specific patient support, including dedicated counselors, multilingual resources, and clear guidance on treatment expectations and long-term monitoring requirements.
For policymakers:
- Incentivize therapy development through frameworks like Orphan Drug Designation.
- Promote equitable access by viewing therapies as long-term healthcare investments.
For patient advocacy groups:
- Amplify patient voices in therapy design.
- Collaborate on patient-reported outcome measures.
Gene and cell therapies are redefining what is possible for patients with rare genetic diseases. Many of these therapies are designed as one-time treatments, which means the window for patient engagement, education, and access is narrow and consequential. Getting it right requires more than scientific innovation. It requires deliberate program design that accounts for affordability, accessibility, and patient understanding from the earliest stages. The full whitepaper outlines how researchers, policymakers, and advocacy groups can work together to close these gaps and deliver on the promise of precision medicine.
Involving patients early in therapy design, through flexible trial formats, at-home testing options, and patient-reported outcome measures, produces evidence that is more relevant to lived experience. It also supports development of therapies that are more likely to reach the people who need them most.